Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 21 | 2020 | 649 | 3.110 |
Why?
|
| Radiosurgery | 15 | 2020 | 360 | 1.960 |
Why?
|
| Cranial Irradiation | 7 | 2020 | 95 | 0.670 |
Why?
|
| Radiotherapy | 1 | 2019 | 90 | 0.570 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 200 | 0.520 |
Why?
|
| Salvage Therapy | 5 | 2020 | 138 | 0.470 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 196 | 0.460 |
Why?
|
| Retrospective Studies | 17 | 2020 | 3812 | 0.460 |
Why?
|
| Middle Aged | 24 | 2020 | 12703 | 0.440 |
Why?
|
| Aged | 19 | 2020 | 10999 | 0.410 |
Why?
|
| Treatment Outcome | 11 | 2020 | 3618 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 399 | 0.400 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 4151 | 0.360 |
Why?
|
| Female | 24 | 2020 | 21491 | 0.340 |
Why?
|
| Neuropsychological Tests | 3 | 2019 | 372 | 0.340 |
Why?
|
| Male | 22 | 2020 | 20697 | 0.330 |
Why?
|
| Prognosis | 9 | 2020 | 1603 | 0.310 |
Why?
|
| Olfaction Disorders | 1 | 2009 | 8 | 0.310 |
Why?
|
| Affective Symptoms | 1 | 2009 | 17 | 0.310 |
Why?
|
| Humans | 26 | 2020 | 34475 | 0.300 |
Why?
|
| Neoplasms | 4 | 2020 | 791 | 0.290 |
Why?
|
| Meningioma | 2 | 2020 | 59 | 0.280 |
Why?
|
| Parkinson Disease | 1 | 2009 | 92 | 0.280 |
Why?
|
| Radiotherapy, Conformal | 2 | 2018 | 18 | 0.280 |
Why?
|
| Adult | 13 | 2020 | 10015 | 0.270 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2366 | 0.260 |
Why?
|
| Survival Rate | 5 | 2020 | 925 | 0.240 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 452 | 0.230 |
Why?
|
| Melanoma | 3 | 2019 | 169 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 231 | 0.170 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 176 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 803 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 88 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 97 | 0.150 |
Why?
|
| Trigeminal Neuralgia | 1 | 2019 | 33 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 18 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 62 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 67 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 62 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2019 | 2461 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 113 | 0.140 |
Why?
|
| Genomics | 1 | 2018 | 94 | 0.130 |
Why?
|
| Hormones | 1 | 2017 | 26 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 74 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 217 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 2017 | 49 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 117 | 0.130 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 70 | 0.130 |
Why?
|
| Survivors | 1 | 2018 | 177 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2018 | 161 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2019 | 390 | 0.120 |
Why?
|
| Quality of Life | 2 | 2019 | 1032 | 0.120 |
Why?
|
| Hippocampus | 1 | 2017 | 225 | 0.120 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2015 | 18 | 0.110 |
Why?
|
| Young Adult | 2 | 2020 | 2825 | 0.110 |
Why?
|
| Sarcoma | 1 | 2015 | 74 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 317 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 350 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 544 | 0.100 |
Why?
|
| Disease Progression | 3 | 2019 | 633 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 25 | 0.090 |
Why?
|
| Radiation Dosage | 2 | 2020 | 96 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 96 | 0.080 |
Why?
|
| Smell | 1 | 2009 | 47 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2020 | 509 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 1289 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 325 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 589 | 0.060 |
Why?
|
| Risk Factors | 2 | 2019 | 4136 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 170 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 110 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 90 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 378 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 104 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 134 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 113 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 34 | 0.030 |
Why?
|
| Radiometry | 1 | 2017 | 52 | 0.030 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 325 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 155 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1354 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 508 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 117 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 576 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1910 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2015 | 57 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 205 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2613 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 1946 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 1031 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 3799 | 0.020 |
Why?
|
| Aminopyrine | 1 | 2012 | 1 | 0.020 |
Why?
|
| Phenylbutazone | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 27 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 107 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 2352 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 196 | 0.020 |
Why?
|
| United States | 1 | 2018 | 4267 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 8544 | 0.010 |
Why?
|